Thursday, November 14, 2019

An Interview with Matthew O’Connor, as Underdog Pharmaceuticals Secures Seed Funding

Matthew O’Conner presented at Undoing Aging earlier this year on the startup biotech company Underdog Pharmaceuticals. The company is spinning out of the SENS Research Foundation (SRF), based on research conducted by the scientific team there in recent years. The company is focused on a class of molecule known cyclodextrins, and have candidates capable of efficiently binding and sequestering 7-ketocholesterol. This form of oxidized cholesterol is of great importance to the progression of atherosclerosis, and possibly other age-related conditions as well. In the case of atherosclerosis, the presence of oxidized cholesterols, and particularly 7-ketocholesterol, causes the macrophage cells, which are responsible for clearing out cholesterol from blood vessel walls, to become dysfunctional and inflammatory. Remove the 7-ketocholestrol, and the problem should largely go away. I’m pleased

From http://besthealthnews.com/2019/11/an-interview-with-matthew-oconnor-as-underdog-pharmaceuticals-secures-seed-funding/?utm_source=rss&utm_medium=rss&utm_campaign=an-interview-with-matthew-oconnor-as-underdog-pharmaceuticals-secures-seed-funding

from
https://healthnews010.wordpress.com/2019/11/15/an-interview-with-matthew-oconnor-as-underdog-pharmaceuticals-secures-seed-funding/

From https://jamesjohnson10.blogspot.com/2019/11/an-interview-with-matthew-oconnor-as.html



from
https://jamesjohnson10.wordpress.com/2019/11/15/an-interview-with-matthew-oconnor-as-underdog-pharmaceuticals-secures-seed-funding/

No comments:

Post a Comment